Quantcast

Latest diabetic neuropathy Stories

2008-11-12 09:00:10

DOYLESTOWN, Pa., Nov. 12 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., a wholly-owned subsidiary of The Quigley Corporation announced today that the last subject in the Phase IIb Study is scheduled to complete treatment on November 25, 2008. This will effectively move the study to the final stage of data collection, evaluation and study conclusions. The Company, after collecting all the patient information from 21 Study centers and conferring with its panel of experts on the data, will...

2008-11-11 09:00:47

Sangamo BioSciences, a developer of novel DNA-binding proteins for therapeutic gene regulation and modification, has announced top-line data from its SB-509-601 clinical trial, one of Sangamo's three Phase II clinical studies from its ZFP therapeutic program to develop SB-509 for diabetic neuropathy. The study is a double-blind, placebo-controlled, repeat-dosing multi- center study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics...

2008-11-10 18:00:05

RICHMOND, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today top-line data from its SB-509-601 clinical trial, one of Sangamo's three Phase 2 clinical studies from its ZFP Therapeutic(TM) program to develop SB-509 for diabetic neuropathy (DN). The data demonstrate that repeat administration of the drug is well tolerated in subjects with mild to moderate DN. However, no significant differences were observed between the SB-509 and placebo treated subjects in...

2008-10-08 09:00:12

XTL Biopharmaceuticals, a developer of therapeutics for the treatment of diabetic neuropathic pain and hepatitis C virus, has announced that the last patient randomized into the Bicifadine Phase IIb clinical trial for the treatment of diabetic neuropathic pain has completed the study. This milestone officially marks the completion of this randomized, double-blind, placebo-controlled Phase IIb clinical trial which enrolled 351 patients at approximately 40 sites in the US, Germany, Israel and...

2008-09-15 12:00:35

RICHMOND, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today the presentation of positive interim Phase 2 clinical data from its ZFP Therapeutic(TM) program (SB-509-701) at the International Society for Cellular Therapy (ISCT) Europe Regional Meeting in Antwerp, Belgium. The data presented demonstrate an improvement in nerve conduction velocity (NCV) in SB-509 treated subjects with moderate to severe diabetic neuropathy (DN), a patient population that until...

2008-09-03 09:00:08

RICHMOND, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today that it has opened a Phase 2 clinical trial (SB-509-801) to evaluate its drug, SB-509, in subjects with ALS, a progressive, degenerative motor-neuron disease for which there are limited treatment options and no cure. Sangamo's drug, SB-509, is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression...

2008-08-25 09:01:58

SUN VALLEY, Calif., Aug. 25 /PRNewswire-FirstCall/ -- XTend Medical Corporation (Pink Sheets: XMDC), a company that delivers cutting-edge telemedicine solutions to the healthcare industry, has secured the exclusive global distribution rights to DDI's Vibration Device for Pre-Screening of Diabetic Neuropathy. The company released the following statement: "XTend Medical is pleased to announce that we have secured the global distribution rights to DDI's patented vibration technology device,...

2008-08-25 09:01:58

XTend Medical has secured the exclusive global distribution rights to DDI's vibration device for pre-screening of diabetic neuropathy. Paul Lisenby, CEO of XTend Medical, said: "Once the FDA has cleared the device for sale, we will immediately begin marketing the product to our managed care companies and the various physicians and patients here in the US. We're also in negotiations to market the product in South Korea and Europe based on their separate criteria needs for final approval....

2008-08-12 09:01:36

Immunosyn Corporation (OTCBB:IMYN) announced today that marketing, distribution and patient treatment approval has been granted by the Ministry of Health Malaysia for SF-1019 in the Private Pay Heath Sector in Malaysia. The marketing name for SF-1019 in Malaysia will be R-1818. Argyll Biotechnologies, LLC, the licensor of SF-1019, Immunosyn's strategic partner and its largest shareholder, has notified Immunosyn that the Ministry of Health Malaysia has approved the importation, marketing...

2008-08-07 15:01:00

The Stanford University Center on Longevity and the U.S. Department of Veterans Affairs Palo Alto Health Care System (VAPAHCS) today announced positive data from their 10-week study of the Cyclic Variations in Altitude Conditioning(TM) (CVAC(TM)) process, CVAC Systems Inc.'s new modality being researched for insulin resistance and diabetes. The blinded, controlled clinical trial, which exposed subjects to the CVAC process for 40 minutes, three times a week for 10 weeks, found that the...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related